8-KFiled Aug 11, 8:00 PM ET

Unicycive Therapeutics Reports Q2 2026 Financial Results

$UNCY · Unicycive Therapeutics, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Unicycive Therapeutics Reports Q2 2026 Financial Results

What Happened

  • On August 12, 2026, Unicycive Therapeutics, Inc. (UNCY) announced its financial results for the quarter ended June 30, 2026 and provided a business update. The company furnished a press release with those results as Exhibit 99.1 to a Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

  • Press release date: August 12, 2026.
  • Quarter covered: Quarter ended June 30, 2026 (Q2 2026).
  • The press release was furnished as Exhibit 99.1 to the Form 8-K (Item 2.02); the filing also includes the Inline XBRL cover page (Item 9.01).
  • This 8-K furnishes the press release (i.e., the release is provided as an exhibit rather than separately filed in a different form).

Why It Matters

  • The announcement provides the company’s latest quarterly results and an operational update that investors can use to assess recent performance and near-term prospects.
  • Investors should read the furnished press release for specifics on revenue, expenses, cash position, clinical or business milestones and any commentary from management. This Form 8-K does not itself include detailed financial tables beyond the press release exhibit.
  • No other material events (such as executive changes, mergers, or bankruptcies) were reported in this filing.